Pros and cons
Pros
- Transparent monthly self-pay pricing on compounded semaglutide: $199 covers visit, prescription, and shipping.
- Operational reliability and customer service is the strongest among compounded-GLP-1 telehealth (Hims/Hers public-company resources).
- Comprehensive intake including BMI, comorbidities, and contraindication screening.
- Branded Wegovy path available if compounded is inappropriate.
- Behavior-coaching support included at the higher tier.
Cons
- Compounded semaglutide is under active FDA enforcement scrutiny; the regulatory environment may change in 2026-2027.
- Black-clinician availability is not surfaced at intake.
- No Medicaid acceptance, which excludes many low-income Black women who would benefit medically.
- Side-effect management for GLP-1 (severe nausea, constipation) is via async messaging, not synchronous clinician access.
Pricing and coverage
- Pricing
- Compounded semaglutide $199/month or branded Wegovy $1,800/month self-pay. Some insurance accepted for branded GLP-1.
- Insurance
- Accepts commercial insurance
- Notes
- Branded Wegovy coverage depends on whether your insurance plan covers GLP-1 for weight loss. Compounded semaglutide is not covered by any insurance and is self-pay only. Medicaid does not cover GLP-1 for weight management in most states.
The 2026 GLP-1 landscape for Black women
Black women have the highest US obesity rate among women (about 57% per CDC 2024). GLP-1 medications represent the first treatment in decades to produce 15-20% sustained weight loss in clinical trials. Access is the issue: branded Wegovy and Zepbound run $1,000-$1,800/month at retail, most commercial insurance does not cover GLP-1 for weight loss, and Medicaid coverage is minimal in most states.
Compounded semaglutide from regulated compounding pharmacies (503A and 503B) became the access pathway for self-pay patients in 2022-2024. Hims Weight Loss is the largest single provider of compounded semaglutide in the US as of 2026.
The regulatory question
FDA declared the semaglutide shortage resolved in October 2024, which technically removed the legal basis for routine compounding. Enforcement has been gradual. As of 2026, compounded semaglutide is still available through services like Hims, but the regulatory ground is moving. If you start on compounded, plan for the possibility that you will need to transition to branded Wegovy or off the medication entirely in 2026-2027.
What the service includes
Standard intake covers BMI, comorbidities, contraindications (pancreatitis history, family history of medullary thyroid carcinoma, pregnancy planning). Dose titration is the standard 0.25 mg / 0.5 mg / 1 mg / 1.7 mg / 2.4 mg weekly schedule. Side-effect management is via async messaging with the clinical team. The higher-tier subscription adds behavior coaching, which Found bundles as standard.
Our methodology
Evaluated against Found, Sesame Care, Henry Meds, Calibrate, and Form Health on cost, regulatory standing, clinician support, and Medicaid acceptance for Black women. October 2026.
Was this helpful?
Your feedback shapes what we cover next.
Thanks for letting us know.
If you found this useful, sign up for our newsletter to get more like this.
Thanks. What was missing?
Optional. We read every response.
Thanks.
We use this to prioritize the next round of edits.